Champions Oncology (CSBR) Income from Continuing Operations (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Income from Continuing Operations of 279000.0 in Q1 2026, down 217.72% quarter-over-quarter from 237000.0 in Q4 2025, and down 106.21% on a YoY basis from 4495000.0 in Q1 2025.
Champions Oncology (CSBR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Champions Oncology's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 279000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 106.21% year-over-year to 279000.0; the TTM figure through Jan 2026 stood at 2343000.0 (down 136.46% YoY), while the FY2025 annual figure was 4701000.0, up 164.61% from the prior year.
- Income from Continuing Operations was 279000.0 for Q1 2026 at Champions Oncology, down from 237000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4495000.0 in Q1 2025 to a low of 2566000.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 469117.65 across 5 years, with a median of 319000.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations tumbled 12843.75% in 2023, then jumped 277.67% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 16000.0 in 2022, then sank by 12843.75% to 2071000.0 in 2023, then soared by 135.15% to 728000.0 in 2024, then tumbled by 67.45% to 237000.0 in 2025, then sank by 217.72% to 279000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 279000.0 (Q1 2026), 237000.0 (Q4 2025), and 466000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Champions Oncology | 82.77 Mn | 75.76 Mn | 13.89 Mn | -279,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -279,000.00 |
| Oct 31, 2025 | 237,000.00 |
| Jul 31, 2025 | -466,000.00 |
| Apr 30, 2025 | -1.84 Mn |
| Jan 31, 2025 | 4.50 Mn |
| Oct 31, 2024 | 728,000.00 |
| Jul 31, 2024 | 1.31 Mn |
| Apr 30, 2024 | -109,000.00 |
| Jan 31, 2024 | -2.53 Mn |
| Oct 31, 2023 | -2.07 Mn |
| Jul 31, 2023 | -2.57 Mn |
| Apr 30, 2023 | -2.56 Mn |
| Jan 31, 2023 | -2.44 Mn |
| Oct 31, 2022 | -16,000.00 |
| Jul 31, 2022 | -319,000.00 |
| Apr 30, 2022 | -344,000.00 |
| Jan 31, 2022 | 787,000.00 |
| Oct 31, 2021 | 277,000.00 |
| Jul 31, 2021 | -172,000.00 |
| Apr 30, 2021 | -673,000.00 |